TY - JOUR A1 - Garitano-Trojaola, Andoni A1 - Sancho, Ana A1 - Götz, Ralph A1 - Eiring, Patrick A1 - Walz, Susanne A1 - Jetani, Hardikkumar A1 - Gil-Pulido, Jesus A1 - Da Via, Matteo Claudio A1 - Teufel, Eva A1 - Rhodes, Nadine A1 - Haertle, Larissa A1 - Arellano-Viera, Estibaliz A1 - Tibes, Raoul A1 - Rosenwald, Andreas A1 - Rasche, Leo A1 - Hudecek, Michael A1 - Sauer, Markus A1 - Groll, Jürgen A1 - Einsele, Hermann A1 - Kraus, Sabrina A1 - Kortüm, Martin K. T1 - Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia JF - Communications Biology N2 - The presence of FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is one of the most frequent mutations in acute myeloid leukemia (AML) and is associated with an unfavorable prognosis. FLT3 inhibitors, such as midostaurin, are used clinically but fail to entirely eradicate FLT3-ITD+AML. This study introduces a new perspective and highlights the impact of RAC1-dependent actin cytoskeleton remodeling on resistance to midostaurin in AML. RAC1 hyperactivation leads resistance via hyperphosphorylation of the positive regulator of actin polymerization N-WASP and antiapoptotic BCL-2. RAC1/N-WASP, through ARP2/3 complex activation, increases the number of actin filaments, cell stiffness and adhesion forces to mesenchymal stromal cells (MSCs) being identified as a biomarker of resistance. Midostaurin resistance can be overcome by a combination of midostaruin, the BCL-2 inhibitor venetoclax and the RAC1 inhibitor Eht1864 in midostaurin-resistant AML cell lines and primary samples, providing the first evidence of a potential new treatment approach to eradicate FLT3-ITD+AML. Garitano-Trojaola et al. used a combination of human acute myeloid leukemia (AML) cell lines and primary samples to show that RAC1-dependent actin cytoskeleton remodeling through BCL2 family plays a key role in resistance to the FLT3 inhibitor, Midostaurin in AML. They showed that by targeting RAC1 and BCL2, Midostaurin resistance was diminished, which potentially paves the way for an innovate treatment approach for FLT3 mutant AML. KW - actin KW - acute myeloid leukaemia Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-260709 VL - 4 IS - 1 ER - TY - JOUR A1 - Brosch, Philippa K. A1 - Korsa, Tessa A1 - Taban, Danush A1 - Eiring, Patrick A1 - Hildebrand, Sascha A1 - Neubauer, Julia A1 - Zimmermann, Heiko A1 - Sauer, Markus A1 - Shirakashi, Ryo A1 - Djuzenova, Cholpon S. A1 - Sisario, Dmitri A1 - Sukhorukov, Vladimir L. T1 - Glucose and inositol transporters, SLC5A1 and SLC5A3, in glioblastoma cell migration JF - Cancers N2 - (1) Background: The recurrence of glioblastoma multiforme (GBM) is mainly due to invasion of the surrounding brain tissue, where organic solutes, including glucose and inositol, are abundant. Invasive cell migration has been linked to the aberrant expression of transmembrane solute-linked carriers (SLC). Here, we explore the role of glucose (SLC5A1) and inositol transporters (SLC5A3) in GBM cell migration. (2) Methods: Using immunofluorescence microscopy, we visualized the subcellular localization of SLC5A1 and SLC5A3 in two highly motile human GBM cell lines. We also employed wound-healing assays to examine the effect of SLC inhibition on GBM cell migration and examined the chemotactic potential of inositol. (3) Results: While GBM cell migration was significantly increased by extracellular inositol and glucose, it was strongly impaired by SLC transporter inhibition. In the GBM cell monolayers, both SLCs were exclusively detected in the migrating cells at the monolayer edge. In single GBM cells, both transporters were primarily localized at the leading edge of the lamellipodium. Interestingly, in GBM cells migrating via blebbing, SLC5A1 and SLC5A3 were predominantly detected in nascent and mature blebs, respectively. (4) Conclusion: We provide several lines of evidence for the involvement of SLC5A1 and SLC5A3 in GBM cell migration, thereby complementing the migration-associated transportome. Our findings suggest that SLC inhibition is a promising approach to GBM treatment. KW - volume regulation KW - transportome KW - phlorizin Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-297498 SN - 2072-6694 VL - 14 IS - 23 ER - TY - THES A1 - Eiring, Patrick T1 - Super-resolution microscopy of plasma membrane receptors T1 - Hochauflösende Mikroskopie von Plasmamembran Rezeptoren N2 - Plasma membrane receptors are the most crucial and most commonly studied components of cells, since they not only ensure communication between the extracellular space and cells, but are also responsible for the regulation of cell cycle and cell division. The composition of the surface receptors, the so-called "Receptome", differs and is characteristic for certain cell types. Due to their significance, receptors have been important target structures for diagnostic and therapy in cancer medicine and often show aberrant expression patterns in various cancers compared to healthy cells. However, these aberrations can also be exploited and targeted by different medical approaches, as in the case of personalized immunotherapy. In addition, advances in modern fluorescence microscopy by so-called single molecule techniques allow for unprecedented sensitive visualization and quantification of molecules with an attainable spatial resolution of 10-20 nm, allowing for the detection of both stoichiometric and expression density differences. In this work, the single molecule sensitive method dSTORM was applied to quantify the receptor composition of various cell lines as well as in primary samples obtained from patients with hematologic malignancies. The focus of this work lies on artefact free quantification, stoichiometric analyses of oligomerization states and co localization analyses of membrane receptors. Basic requirements for the quantification of receptors are dyes with good photoswitching properties and labels that specifically mark the target structure without generating background through non-specific binding. To ensure this, antibodies with a predefined DOL (degree of labeling) were used, which are also standard in flow cytometry. First background reduction protocols were established on cell lines prior analyses in primary patient samples. Quantitative analyses showed clear expression differences between the cell lines and the patient cells, but also between individual patients. An important component of this work is the ability to detect the oligomerization states of receptors, which enables a more accurate quantification of membrane receptor densities compared to standard flow cytometry. It also provides information about the activation of a certain receptor, for example of FLT3, a tyrosine kinase, dimerizing upon activation. For this purpose, different well-known monomers and dimers were compared to distinguish the typical localization statistics of single bound antibodies from two or more antibodies that are in proximity. Further experiments as well as co localization analyses proved that antibodies can bind to closely adjacent epitopes despite their size. These analytical methods were subsequently applied for quantification and visualization of receptors in two clinically relevant examples. Firstly, various therapeutically relevant receptors such as CD38, BCMA and SLAMF7 for multiple myeloma, a malignant disease of plasma cells, were analyzed and quantified on patient cells. Furthermore, the influence of TP53 and KRAS mutations on receptor expression levels was investigated using the multiple myeloma cell lines OPM2 and AMO1, showing clear differences in certain receptor quantities. Secondly, FLT3 which is a therapeutic target receptor for acute myeloid leukemia, was quantified and stoichiometrically analyzed on both cell lines and patient cells. In addition, cells that have developed resistance against midostaurin were compared with cells that still respond to this type I tyrosine-kinase-inhibitor for their FLT3 receptor expression and oligomerization state. N2 - Plasmamembranrezeptoren sind die wohl wichtigsten und meist untersuchten Komponenten einer Zelle, da sie nicht nur die Kommunikation zwischen dem extrazellulären Bereich und den Zellen gewährleisten, sondern auch für die Regulierung des Zellzyklus und der Zellteilung zuständig sind. Dabei unterscheidet sich die Zusammensetzung der Oberflächenrezeptoren, das sogenannte „Rezeptom“, und ist charakteristisch für bestimme Zelltypen. Aufgrund ihrer Bedeutsamkeit sind Rezeptoren wichtige Zielstrukturen für Diagnose und Therapie in der Krebsmedizin, welche häufig bei verschiedensten Krebserkrankungen im Vergleich zu gesunden Zellen aberrante Expressionsmuster aufweisen. Diese Abweichungen können sich allerdings auch zu Nutze gemacht werden und zum Ziel verschiedener medizinischer Behandlungsmethoden, wie es bei der personalisierten Immuntherapie der Fall ist, werden. Zusätzlich hat der Fortschritt in der modernen Fluoreszenzmikroskopie durch sogenannte Einzelmolekültechniken, es auch erlaubt, eine noch nie dagewesene empfindliche Visualisierung und Quantifizierung von Molekülen mit einer räumlichen Auflösung von 10-20 nm zu erreichen, wodurch sowohl stöchiometrische Unterschiede, als auch Unterschiede in der Expressionsdichte detektiert werden können. In dieser Arbeit wurde die einzelmolekülsensitive Methode dSTORM genutzt, um die Rezeptorkomposition von verschiedenen Zelllinien aber auch von primären Patientenzellen mit zugrundeliegenden hämatologischen Erkrankungen zu quantifizieren. Schwerpunkte dieser Arbeit sind dabei die artefaktfreie Quantifizierung, stöchiometrische Analysen von Oligomerisierungszuständen, sowie die Kolokalisationsanalyse von Membranrezeptoren. Grundvoraussetzung für die Quantifizierung von Rezeptoren sind dabei gut schaltbare Farbstoffe, sowie Label, welche die Zielstruktur spezifisch markieren ohne dabei Hintergrund durch unspezifische Bindung zu generieren. Um dies zu gewährleisten, kamen Antikörper mit einem vordefinierten DOL (degree of labeling; engl. für: Markierungsgrad) zum Einsatz, welche auch in der Durchflusszytometrie standardmäßig eingesetzt werden. Protokolle zur Hintergrundreduktion wurden dabei an Zelllinien etabliert, bevor Primärzellen von Krebspatienten analysiert wurden. Durch quantitative Analysen konnten dabei deutliche Expressionsunterschiede zwischen den Zelllinien und den Patientenzellen, aber auch zwischen den verschiedenen Patienten gezeigt werden. Ein wichtiger Bestandteil dieser Arbeit ist die Fähigkeit, den Oligomerisierungszustand von Rezeptoren zu erkennen, was eine genauere Quantifizierung der Membran-rezeptordichten im Vergleich zur Durchflusszytometrie ermöglicht. Allerdings können diese Oligomerisierungszustände auch Informationen über die Aktivierung eines Rezeptors beinhalten, wie zum Beispiel von FLT3, einer Tyrosinkinase, welche zur Aktivierung dimerisieren muss. Hierfür wurden verschiedene bekannte Monomere und Dimere verglichen, um die typische Lokalisationsstatistik von vereinzelten gebundenen Antikörpern mit der von zwei oder mehr Antikörpern, welche nah beieinanderliegen, zu vergleichen. Durch weitere Etablierungsexperimente sowie Kolokalisationsanalysen konnte außerdem bewiesen werden, dass Antikörper trotz ihrer Größe auch an nah benachbarte Epitope binden können. Diese Analyseverfahren wurden im weiteren Verlauf zur Quantifizierung und Visualisierung von Rezeptoren an zwei klinisch relevanten Beispielen angewendet. Zum einen wurden verschiedene therapeutisch relevante Rezeptoren wie z.B. CD38, BCMA und SLAMF7 für das Multiple Myelom, einer malignen Erkrankung von Plasmazellen, auf Patientenzellen analysiert und quantifiziert. Zusätzlich wurde der Einfluss von TP53 und KRAS Mutationen auf die Rezeptorexpressionen anhand der Multiplen Myelom Zelllinien OPM2 und AMO1 untersucht, bei denen eindeutige Unterschiede in der Rezeptorexpression detektiert wurden. Zum anderen wurde FLT3, welches ein therapeutischer Zielrezeptor für die akute myeloische Leukämie ist, sowohl auf Zelllinien als auch auf Patientenzellen quantifiziert und stöchiometrisch analysiert. Hierbei wurden auch Zellen welche eine Midostaurinresistenz entwickelt haben mit Zellen, welche auf diesen Typ I Tyrosinkinase Inhibitor ansprechen, auf ihre FLT3 Rezeptorexpression und ihren Oligomerisierungszustand verglichen. KW - Fluoreszenzmikroskopie KW - Membranrezeptor KW - Hochaufgelöste Fluoreszenzmikroskopie KW - Super-resolution microscopy KW - Membrane receptor Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-250048 ER - TY - JOUR A1 - Eiring, Patrick A1 - McLaughlin, Ryan A1 - Matikonda, Siddharth S. A1 - Han, Zhongying A1 - Grabenhorst, Lennart A1 - Helmerich, Dominic A. A1 - Meub, Mara A1 - Beliu, Gerti A1 - Luciano, Michael A1 - Bandi, Venu A1 - Zijlstra, Niels A1 - Shi, Zhen-Dan A1 - Tarasov, Sergey G. A1 - Swenson, Rolf A1 - Tinnefeld, Philip A1 - Glembockyte, Viktorija A1 - Cordes, Thorben A1 - Sauer, Markus A1 - Schnermann, Martin J. T1 - Targetable conformationally restricted cyanines enable photon-count-limited applications JF - Angewandte Chemie Internationale Edition N2 - Cyanine dyes are exceptionally useful probes for a range of fluorescence-based applications, but their photon output can be limited by trans-to-cis photoisomerization. We recently demonstrated that appending a ring system to the pentamethine cyanine ring system improves the quantum yield and extends the fluorescence lifetime. Here, we report an optimized synthesis of persulfonated variants that enable efficient labeling of nucleic acids and proteins. We demonstrate that a bifunctional sulfonated tertiary amide significantly improves the optical properties of the resulting bioconjugates. These new conformationally restricted cyanines are compared to the parent cyanine derivatives in a range of contexts. These include their use in the plasmonic hotspot of a DNA-nanoantenna, in single-molecule Förster-resonance energy transfer (FRET) applications, far-red fluorescence-lifetime imaging microscopy (FLIM), and single-molecule localization microscopy (SMLM). These efforts define contexts in which eliminating cyanine isomerization provides meaningful benefits to imaging performance. KW - biology KW - super-resolution microscopy KW - conformational restriction KW - cyanine dyes KW - DNA nanotechnology KW - fluorescent dyes KW - single-molecule fluorescence spectroscopy Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-256559 VL - 60 IS - 51 ER - TY - JOUR A1 - Haake, Markus A1 - Haack, Beatrice A1 - Schäfer, Tina A1 - Harter, Patrick N. A1 - Mattavelli, Greta A1 - Eiring, Patrick A1 - Vashist, Neha A1 - Wedekink, Florian A1 - Genssler, Sabrina A1 - Fischer, Birgitt A1 - Dahlhoff, Julia A1 - Mokhtari, Fatemeh A1 - Kuzkina, Anastasia A1 - Welters, Marij J. P. A1 - Benz, Tamara M. A1 - Sorger, Lena A1 - Thiemann, Vincent A1 - Almanzar, Giovanni A1 - Selle, Martina A1 - Thein, Klara A1 - Späth, Jacob A1 - Gonzalez, Maria Cecilia A1 - Reitinger, Carmen A1 - Ipsen-Escobedo, Andrea A1 - Wistuba-Hamprecht, Kilian A1 - Eichler, Kristin A1 - Filipski, Katharina A1 - Zeiner, Pia S. A1 - Beschorner, Rudi A1 - Goedemans, Renske A1 - Gogolla, Falk Hagen A1 - Hackl, Hubert A1 - Rooswinkel, Rogier W. A1 - Thiem, Alexander A1 - Romer Roche, Paula A1 - Joshi, Hemant A1 - Pühringer, Dirk A1 - Wöckel, Achim A1 - Diessner, Joachim E. A1 - Rüdiger, Manfred A1 - Leo, Eugen A1 - Cheng, Phil F. A1 - Levesque, Mitchell P. A1 - Goebeler, Matthias A1 - Sauer, Markus A1 - Nimmerjahn, Falk A1 - Schuberth-Wagner, Christine A1 - Felten, Stefanie von A1 - Mittelbronn, Michel A1 - Mehling, Matthias A1 - Beilhack, Andreas A1 - van der Burg, Sjoerd H. A1 - Riedel, Angela A1 - Weide, Benjamin A1 - Dummer, Reinhard A1 - Wischhusen, Jörg T1 - Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment JF - Nature Communications N2 - Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development. KW - cancer microenvironment KW - immunotherapy KW - T cells KW - tumour immunology Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357333 VL - 14 ER -